Read the original article here. Hamilton Morris is a trusted resource for millions worldwide as a psychoactive substances’ expert, who is at the forefront of the psychedelic movement. He’s a chemist, filmmaker, and science journalist. He is also the director of the award-winning documentary series Hamilton’s Pharmacopeia in which he explores the chemistry and traditions surrounding psychoactive drugs.
Hamilton attended the University of Chicago and The New School in New York City, where he studied anthropology and science. He frequently consults with media on the subject of psychoactive drugs and conducts pharmacological research at the University of the Sciences in Philadelphia. His research has allowed him to study psychoactive plants, fungi, and chemicals as well as the culture that surrounds them.
In his role as advisor, Mr. Morris will bring his renowned scientific and anthropological approach to Mind Cure, and in so doing will support the team in advising on new product candidate opportunities and their merits. Mr. Morris has been an active member of the scientific community during the psychedelic renaissance and is well respected for both his novel and disciplined, science-first position in its advancement.
Hamilton said, “The potential of psychedelics and new medicines to treat mental illness is significant,” and continued, “As a researcher and journalist, my work is always driven by science. I look forward to working with the team at Mind Cure as they research and discover new products to treat mental health.”
With Hamilton, Mind Cure intends to further its investigation into new product candidates and treatments which are effective in treating mental health. These new product candidates range from nootropics to psychoactive products and psychedelic substances.
Mind Cure’s mission is to identify, develop and commercialize products that enhance mental health and wellness, ease suffering and increase productivity. Their website says they were, “formed as a response to a world suffering from mental health crisis and in urgent need of effective treatments.
The question remains whether or not the people who are suffering actually want or can even afford these new treatment options. Time will tell, but it is nice to see mental health companies taking on advisors who are pioneers in the industry.